about
The expression of the phosphotyrosine phosphatase DEP-1/PTPeta dictates the responsivity of glioma cells to somatostatin inhibition of cell proliferationMinimalist hybrid ligand/receptor-based pharmacophore model for CXCR4 applied to a small-library of marine natural products led to the identification of phidianidine a as a new CXCR4 ligand exhibiting antagonist activity.Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target.CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment.CXCR4 expression in feline mammary carcinoma cells: evidence of a proliferative role for the SDF-1/CXCR4 axis.An interaction between hepatocyte growth factor and its receptor (c-MET) prolongs the survival of chronic lymphocytic leukemic cells through STAT3 phosphorylation: a potential role of mesenchymal cells in the diseaseIn vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumorsMetformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt.Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures.Inhibition of the Autophagy Pathway Synergistically Potentiates the Cytotoxic Activity of Givinostat (ITF2357) on Human Glioblastoma Cancer Stem Cells.Cellular prion protein controls stem cell-like properties of human glioblastoma tumor-initiating cellsChemokines and chemokine receptors: new actors in neuroendocrine regulations.The status of the art of human malignant glioma management: the promising role of targeting tumor-initiating cells.Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies.New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells.Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 System.Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds.The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.Adiponectin as novel regulator of cell proliferation in human glioblastoma.Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity.Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets.17A, a novel non-coding RNA, regulates GABA B alternative splicing and signaling in response to inflammatory stimuli and in Alzheimer disease.17beta-estradiol promotes breast cancer cell proliferation-inducing stromal cell-derived factor-1-mediated epidermal growth factor receptor transactivation: reversal by gefitinib pretreatment.SDF-1 controls pituitary cell proliferation through the activation of ERK1/2 and the Ca2+-dependent, cytosolic tyrosine kinase Pyk2.Expression of CXC chemokine receptors 1-5 and their ligands in human glioma tissues: role of CXCR4 and SDF1 in glioma cell proliferation and migration.Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation.The phosphotyrosine phosphatase eta mediates somatostatin inhibition of glioma proliferation via the dephosphorylation of ERK1/2.Quinolizidinyl derivatives of iminodibenzyl and phenothiazine as multidrug resistance modulators in ovarian cancer cells.The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cellsPersistent increase of D-aspartate in D-aspartate oxidase mutant mice induces a precocious hippocampal age-dependent synaptic plasticity and spatial memory decay.Establishment and characterization of three new cell lines derived from the ascites of human ovarian carcinomas.Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation.Unsymmetrical methylene derivatives of indoles as antiproliferative agents.Amyloid-β protein precursor regulates phosphorylation and cellular compartmentalization of microtubule associated protein tau.Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity.Isolation of stem-like cells from spontaneous feline mammary carcinomas: phenotypic characterization and tumorigenic potential.Somatostatin receptors 1, 2, and 5 cooperate in the somatostatin inhibition of C6 glioma cell proliferation in vitro via a phosphotyrosine phosphatase-eta-dependent inhibition of extracellularly regulated kinase-1/2.
P50
Q28259893-BFDF8CF2-2681-491C-9690-AAC624F5E1A6Q30671997-A4DD5B2C-C385-44A5-A524-1149C5444B65Q33559560-84B89286-3F74-4DAB-BBBB-CBB81B9E5675Q33677057-FBC3C755-0A39-4C03-9A5F-40BC75EF815FQ34195197-BCE27988-24F6-495B-B0CB-089AEBC69DFCQ35082524-A1D19D0A-E978-41E6-9873-7B69AA0E9FC3Q35425337-DD1B6656-7ED5-4F39-8220-9E46C06E1313Q36604614-A749082C-65A8-498A-8495-7F2DD71F3684Q36654402-9A05F6EE-BC3B-4A01-A434-CF3BFCCC1E90Q37368670-C35D969D-468E-49CE-BF0E-BCC966E72BB1Q37437614-8567EEF7-2385-4E40-B082-64684403F31FQ37771976-59E7FF3F-EF73-4E65-A4D8-148EC0322561Q38019237-31953C34-E32B-4E66-9444-348478416101Q38156506-8735FEAC-E520-40B4-9E49-99055EAAEDC2Q38187997-490293A7-3452-4265-9E36-5C51C6E4B380Q38284921-E273A2CA-5169-4686-AF02-C4A0E999EB10Q38604588-B0BBBCD5-6D50-4A89-873E-BC31FBE2C217Q38819651-FA7FFD76-3802-4569-AAFD-55333F5ADA24Q38947056-90FAF498-7E7B-4A4F-A524-4EBF66FC93FBQ39013719-E4DDE3F2-2D2E-4945-B53B-D6FFDAC5D835Q39071024-6018ACEA-EB65-45E9-A36F-058BF618A39FQ39156308-B0D665B3-747C-4B27-BB5B-89E08F434B02Q39501185-FAE5A5A7-D8C6-4E46-B4EE-9F0E27C88348Q39648917-B2BF668A-CCF5-4782-918E-9D48C38F19C0Q40062740-58522226-97B8-4015-B57B-F7447675DD56Q40154392-2B2C0E25-9990-48FA-B0EE-7769A553FE52Q40290961-C9717DCE-57A4-4834-B092-441D3639E6CDQ40416189-3A888B5F-71D6-4390-B868-4F807DE8A7BEQ40468850-8FD4E857-999F-4B65-B77D-0D29AA179A96Q40621431-145FEE1B-962A-411B-93DC-BDAC5E0BD348Q42038363-BAC5BC55-9CED-4B6E-842F-E3FB9F55B9D2Q42464852-4EDBC843-31B0-44AB-A56F-3A820BADDD1EQ42811851-9D81D7B5-7DB5-4474-BCBF-CF387EEB676DQ43188666-16252AC2-66C3-47F9-A90A-BF9E95218796Q43832559-EE6CF122-C4EB-4D98-BD6C-B869BA08CCAEQ44315466-0EE908F3-AF80-4712-9ECD-88C658C12DE2Q44478607-EA73D742-1ED9-4ADA-897E-C8B00FDFECEBQ44796383-6522342F-DE2B-4546-9537-64C43C0CA764Q44823654-EFA74597-3625-45DA-9475-4E626AC27D41Q46530142-DBD5DCAA-23FB-4F18-B09F-5BC935346FD5
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Federica Barbieri
@ast
Federica Barbieri
@en
Federica Barbieri
@es
Federica Barbieri
@sl
type
label
Federica Barbieri
@ast
Federica Barbieri
@en
Federica Barbieri
@es
Federica Barbieri
@sl
prefLabel
Federica Barbieri
@ast
Federica Barbieri
@en
Federica Barbieri
@es
Federica Barbieri
@sl
P1053
L-8753-2015
P106
P1153
7006991204
P21
P2798
P31
P3829
P496
0000-0001-8988-6896